-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing Seagen (NASDAQ:SGEN) and OKYO Pharma (NASDAQ:OKYO)
Reviewing Seagen (NASDAQ:SGEN) and OKYO Pharma (NASDAQ:OKYO)
OKYO Pharma (NASDAQ:OKYO – Get Rating) and Seagen (NASDAQ:SGEN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Earnings and Valuation
This table compares OKYO Pharma and Seagen's revenue, earnings per share and valuation.
Get OKYO Pharma alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OKYO Pharma | N/A | N/A | -$5.43 million | N/A | N/A |
Seagen | $1.57 billion | 14.98 | -$674.47 million | ($3.45) | -36.82 |
OKYO Pharma has higher earnings, but lower revenue than Seagen.
Profitability
This table compares OKYO Pharma and Seagen's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
OKYO Pharma | N/A | N/A | N/A |
Seagen | -34.16% | -21.56% | -17.46% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for OKYO Pharma and Seagen, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OKYO Pharma | 0 | 0 | 0 | 0 | N/A |
Seagen | 0 | 4 | 11 | 0 | 2.73 |
Seagen has a consensus price target of $160.67, indicating a potential upside of 26.49%. Given Seagen's higher possible upside, analysts plainly believe Seagen is more favorable than OKYO Pharma.
Institutional and Insider Ownership
0.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 86.3% of Seagen shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 27.3% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
OKYO Pharma beats Seagen on 5 of the 9 factors compared between the two stocks.
About OKYO Pharma
(Get Rating)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
About Seagen
(Get Rating)
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
OKYO Pharma (NASDAQ:OKYO – Get Rating) and Seagen (NASDAQ:SGEN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
奧喬製藥(納斯達克:Okyo-Get評級)和賽根(納斯達克:SKEN-GET評級)都是醫療公司,但哪一項投資更具優勢?我們將根據這兩家公司的機構所有權、估值、風險、收益、股息、盈利能力和分析師的建議來比較它們的實力。
Earnings and Valuation
收益和估值
This table compares OKYO Pharma and Seagen's revenue, earnings per share and valuation.
該表格比較了Okyo Pharma和Seagen的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OKYO Pharma | N/A | N/A | -$5.43 million | N/A | N/A |
Seagen | $1.57 billion | 14.98 | -$674.47 million | ($3.45) | -36.82 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
大代藥業 | 不適用 | 不適用 | -543萬美元 | 不適用 | 不適用 |
海洋發電公司 | 15.7億美元 | 14.98 | -6.7447億美元 | ($3.45) | -36.82 |
OKYO Pharma has higher earnings, but lower revenue than Seagen.
Okyo Pharma的收益比Seagen高,但收入比Seagen低。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
OKYO Pharma | N/A | N/A | N/A |
Seagen | -34.16% | -21.56% | -17.46% |
淨利潤率 | 股本回報率 | 資產回報率 | |
大代藥業 | 不適用 | 不適用 | 不適用 |
海洋發電公司 | -34.16% | -21.56% | -17.46% |
Analyst Recommendations
分析師建議
This is a breakdown of recent recommendations and price targets for OKYO Pharma and Seagen, as reported by MarketBeat.com.
據MarketBeat.com報道,這是對Okyo Pharma和Seagen的最近建議和目標價的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OKYO Pharma | 0 | 0 | 0 | 0 | N/A |
Seagen | 0 | 4 | 11 | 0 | 2.73 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
大代藥業 | 0 | 0 | 0 | 0 | 不適用 |
海洋發電公司 | 0 | 4 | 11 | 0 | 2.73 |
Seagen has a consensus price target of $160.67, indicating a potential upside of 26.49%. Given Seagen's higher possible upside, analysts plainly believe Seagen is more favorable than OKYO Pharma.
SeaGen的一致目標價為160.67美元,表明潛在上行26.49%。考慮到Seagen更有可能的上行空間,分析師們顯然認為Seagen比Okyo Pharma更有利。
Institutional and Insider Ownership
機構和內部人持股
0.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 86.3% of Seagen shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 27.3% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Okyo Pharma 0.0%的股份由機構投資者持有。相比之下,Seagen 86.3%的股份由機構投資者持有。Okyo Pharma 40.5%的股份由內部人士持有。相比之下,Seagen 27.3%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司有望實現長期增長。
Summary
摘要
OKYO Pharma beats Seagen on 5 of the 9 factors compared between the two stocks.
在比較兩隻股票的9個因素中,Okyo Pharma有5個勝過Seagen。
About OKYO Pharma
大代製藥公司簡介
(Get Rating)
(獲取評級)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Okyo Pharma Limited是一家臨牀前生物製藥公司,致力於為英國患有炎症性眼病和眼痛的患者開發治療藥物。其主導產品包括用於治療乾眼病的OK-101。該公司還在開發OK-201,一種牛腎上腺髓質,脂化肽臨牀前類似物,用於治療神經性眼痛。奧喬製藥有限公司成立於2007年,總部設在英國倫敦。
About Seagen
關於西根
(Get Rating)
(獲取評級)
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
SeaGen公司是一家生物技術公司,在美國和國際上開發和銷售治療癌症的療法。該公司提供用於治療霍奇金淋巴瘤或CD30陽性T細胞淋巴瘤患者的抗體-藥物結合物(ADC)Adcetris;用於治療晚期或轉移性尿路上皮癌的靶向Nectin-4的ADC PADCEV;以及用於治療晚期不可切除或轉移性HER2陽性乳腺癌的口服小分子酪氨酸激酶抑制劑TUKYSA。它還開發了用於治療轉移性宮頸癌和其他實體腫瘤的TIVDAK;針對轉移性乳腺癌和實體腫瘤Liv-1的ADC Ladiratuzumab Vedotin;針對HER2靶向的新型ADC Disitamab Vedotin;以及用於各種癌症疾病的SEA-CD40、SEA-TGT、SEA-BCMA和SEA-CD70。SeaGen Inc.與武田製藥有限公司、Agensys公司、Genmab A/S公司、默克公司和RomeGen有限公司簽訂了合作協議。該公司的前身是西雅圖遺傳公司,並於2020年10月更名為Seagen Inc.。SeaGen Inc.成立於1997年,總部設在華盛頓州博塞爾。
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大代醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Okyo Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧